Germline aryl hydrocarbon receptor interacting protein (AIP) gene mutations confer a predisposition to pituitary adenoma (PA), predominantly GH-secreting (GH-PA). As recent data suggest a role for AIP in the pathogenesis of sporadic GH-PA and their response to somatostatin analogues (SSA), the expression of AIP and its partner, aryl hydrocarbon receptor (AHR), was determined by semiquantitative immunohistochemistry scoring in 62 sporadic GH-PA (37 treated with SSA preoperatively). The influence of Gsp status was studied in a subset of tumours (nZ39, 14 Gsp C ) and six GH-PA were available for primary cultures. AIP and AHR were detected in most cases, with a positive correlation between AIP and cytoplasmic AHR (PZ0.012). Low AIP expression was significantly more frequent in untreated vs SSA-treated tumours (44.0 vs 20.5%, PZ0.016). AHR expression or localisation did not differ between the two groups. Similarly, in vitro octreotide induced a median twofold increase in AIP expression (range 1.2-13.9, PZ0.027) in GH-PA. In SSA-treated tumours, the AIP score was significantly higher in the presence of preoperative IGF1 decrease or tumour shrinkage (PZ0.008 and PZ0.014 respectively). In untreated tumours, low AIP expression was significantly associated with invasiveness (PZ0.028) and suprasellar extension (PZ0.019). The only effect of Gsp status was a significantly lower nuclear AHR score in Gsp C vs Gsp K tumours (PZ0.025), irrespective 
Introduction
The aryl hydrocarbon receptor interacting protein (AIP) gene has been identified as a predisposing gene for the development of pituitary adenomas (PA) (Vierimaa et al. 2006) . AIP is a pituitary tumour suppressor gene, with germline inactivating mutations being associated with somatic loss of heterozygosity in the corresponding tumours. A particular preponderance of growth hormone (GH)-secreting PA (GH-PA) in the setting of germline AIP mutations (AIP mut ) has been reported by clinical studies worldwide (Beckers et al. 2013) . In our experience, germline AIP mut accounts for 50% of familial isolated PA kindreds with homogeneous somatotropinomas ) and 80% of AIP mut patients with PA have GH-PA . AIP mut GH-PA can also present as an apparently sporadic acromegaly or gigantism in young patients, especially in a paediatric context (Beckers et al. 2013) . When compared with their non-AIP mut counterparts, AIP mut somatotropinomas are commonly more aggressive and more frequently resistant to somatostatin analogues (SSA; Daly et al. 2010 ).
There is a growing body of evidence that AIP downregulation may contribute to the pathogenesis of sporadic PA, regardless of AIP mut status. Although somatic AIP mutations have not been reported to date (Barlier et al. 2007 , Iwata et al. 2007 , Jaffrain-Rea et al. 2009 ), AIP expression is frequently reduced in invasive GH-PA (Jaffrain-Rea et al. 2009) , and loss of AIP immunostaining has been proposed as a marker of tumour aggressiveness in sporadic cases (Kasuki Jomori de Pinho et al. 2011) . There is also recent evidence that AIP expression is increased by SSA and may predict the post-operative response to SSA in acromegalic patients (Kasuki et al. 2012) . This suggests that loss of AIP function or expression may contribute to pharmacological resistance in GH-PA. We have previously observed that AIP mutations or down-regulation in PA is frequently accompanied by a reduced expression of its best characterised partner, the aryl hydrocarbon receptor (AHR; Jaffrain-Rea et al. 2009) . AHR is stabilised in the cytoplasm into a latent AIP/AHR/heatshock protein 90/p23 complex (Petrulis & Perdrew 2002) . Upon activation by exogenous ligands, it translocates to the nucleus and exerts transcriptional effects after heterodimerisation with the aryl hydrocarbon receptor nuclear translocator (ARNT; Beischlag et al. 2008) . The AHR/ARNT complex mediates the detoxifying effects of AHR and is involved in endocrine disruption (Beischlag et al. 2008) . Endogenous functions of AHR include the control of apoptosis and cell cycle proliferation (Nguyen & Bradfield 2008) and AHR signalling may up-regulate p27
Kip1 (Marlowe & Puga 2005) , which is also increased by SSA in GH-PA (Ferrante et al. 2006 , Hubina et al. 2006 . However, the potential effects of SSA on AHR expression and localisation in GH-PA is unknown. The best understood genetic event in sporadic GH-PA is the presence of somatic activating mutations of the GNAS1 (GNAS) gene -the Gsp oncogene -which induce a constitutive activity of the cAMP pathway, an important target of SSA (Lania et al. 2003) . As cAMP is an endogenous activator of AHR (Oesch-Bartlomowicz et al. 2005) and cAMP signalling can be modulated by AIP through direct interactions with specific phosphodiesterases (PDEs; Bolger et al. 2003 , de Oliveira et al. 2007 , Gsp may also theoretically affect AIP and/or AHR expression.
We therefore aimed to further evaluate the expression of AIP and AHR in a large series of sporadic GH-PA, taking into account the presence of preoperative SSA treatment and the potential effects of Gsp mutations.
Subjects and methods

Patients and samples
A series of surgical samples from 62 GH-PA operated on in patients with sporadic acromegaly was retrospectively studied, including 52 cases from three European centres (Neuromed, Pozzilli and University/Hospital of Padova, Italy; CHU, University of Liège, Belgium) and ten tumours with Gsp mutations (Gsp C ) provided by additional two centres (University of Aix-Marseilles, France and University of Milan, Italy). Most tumours were collected between 2006 and 2011; archive material collected from 1997 to 2005 was included in order to ensure an appropriate ratio of SSA-treated and -untreated tumours and a sufficient number of Gsp C samples. The study was approved by local ethics committees. Patients diagnosed before the age of 18 years, with a familial history of acromegaly or with germline AIP mutations, were excluded from the study, as well as those who received preoperative therapy with dopamine agonists only. Of the patients, 25 were males and 37 were females, with a mean age of 44.8G12.8 years at surgery (median 44.5 years and range 18-78 years). Patients' clinical, biological and neuroradiological data were recorded. GH, prolactin (PRL) and insulin-like growth factor 1 (IGF1) measurements were obtained for each centre. IGF1 levels were adjusted for age and expressed as percentage of upper normal limit (%ULN). Hormone data were incomplete in 12 cases. Most patients had macroadenomas, as defined by maximal tumour diameter exceeding 10 mm (52 out of 62 cases, 83.9%), a suprasellar extension was recorded in 29 out of 59 cases (49.1%) -not recorded in three cases -and 31 out of 62 cases (50%) were invasive. A total of 37 patients (59.7%) received SSA treatment before surgery (octreotide-LAR 20-40 mg monthly, nZ21 or lanreotide 60-120 mg monthly, nZ16), including four patients who also received dopamine agonists for mixed GH/PRL-secreting tumours. Median preoperative treatment duration was 6 months (range 3-108). The pharmacological response was assessed in terms of plasma GH and IGF1 reduction, hormone values at diagnosis and before surgery being available for 33 treated patients to calculate DGH and DIGF1 as percentages of hormone decrease. Treated patients were then divided into three groups on the basis of preoperative age-corrected IGF1 values (%ULN): group I, controlled (IGF1 normalisation for age, nZ10); group II, partially controlled (non-normalised IGF1 with DIGF1 R30% when compared with pretreatment values, nZ13) and group III, uncontrolled (DIGF1 !30% or IGF1 increase when compared with pretreatment values, nZ10). Data on tumour shrinkage were also available for 26 patients (including one patient with no available DIGF1). Immunohistochemistry (IHC) for pituitary hormones was performed in each centre. Cell proliferation was evaluated in 54 cases by Ki67 immunostaining with the monoclonal MIB1 antibody, as described previously (Jaffrain-Rea et al. 2002) .
Molecular and genetic analysis
Patients gave informed consent for genetic analysis. Direct AIP sequencing was performed on leukocyte DNA as previously reported , Occhi et al. 2010 . A search for activating mutations of the GNAS1 gene at codons 201 and 227 (Gsp) was performed on tumour DNA at each centre, as described previously (Barlier et al. 1998 , Lania et al. 1998 , Occhi et al. 2011 , primers and conditions for GNAS1 sequencing in the leading centre being available on demand. In a minority of patients lost to follow-up, AIP and GNAS1 sequencing was performed on tumour DNA obtained from paraffin-embedded material (QIAmp DNA FFPE tissue kit, Qiagen). Overall, AIP and GNAS1 sequences could be obtained in 40 and 39 cases respectively, 29 being characterised for both genes. No case had an AIP mutation, and no significant difference was retrospectively found between tumours characterised or not for AIP sequencing in terms of patient's age, gender, tumour volume, invasiveness and preoperative SSA treatment (data not shown). Gsp mutations were present in 14/39 cases (Gsp C ).
Immunohistochemistry
IHC was performed at the University of L'Aquila as described previously (Jaffrain-Rea et al. 2009) using a mouse monoclonal anti-AIP antibody at a 1:500 dilution in all cases (clone 35-2, Novus Biologicals LLC, Littleton, CO, USA, distributed by DBA Italia, Milan, Italy) and a polyclonal rabbit anti-AHR antibody at a 1:50 dilution in 53 cases (sc-5579, Santa Cruz Biotechnology, distributed by DBA Italia). Negative controls were performed omitting the primary antibody and normal pituitary (NP) tissue adjacent to PA samples was used as positive controls.
Immunostaining for AIP was classified semiquantitatively according to intensity (negative, 0; weak, 1; moderate, 2 and strong, 3) and expression pattern (patchy, 1 and diffuse, 2), with a final score being obtained by multiplying intensity!pattern (range 0-6) (Leontiou et al. 2008 , Kasuki Jomori de Pinho et al. 2011 . Low AIP immunostaining (low AIP-IHC) was defined by a semiquantitative score %2. AHR immunostaining was also classified semiquantitatively (negative, 0; weak, 1; moderate, 2 and strong, 3) in terms of cytoplasmic AHR (AHRc) and nuclear AHR (AHRn) localisation. Total AHR (AHRt) score was calculated by adding AHRc and AHRn scores. High AHRc and AHRn scores were defined as R2 and high AHR content (high AHR-IHC) by AHRt score R4. Photographs of slides were taken using a Zeiss Axioplan 2 microscope (Carl Zeiss Microimaging, Inc., USA) and a Leica DFC 320 digital camera (Leica GmBH, Germany).
In vitro study of GH-secreting PA
The study was previously approved by the local ethics committees at the Universities of Milan and Marseilles and informed consent was obtained from the patients. Fresh tissue was obtained by the transsphenoidal route from six untreated GH-PA and enzymatically dissociated in DMEM containing 2 mg/ml collagenase at 37 8C for 2 h, as described previously (Lania et al. 2004) . Cells from two GH-PA were incubated with or without octreotide (10 nM) for 6, 24 and 48 h and lysed in the presence of protease inhibitors. On the basis of these experiments and due to limited amounts of cells, four additional tumours were studied at baseline and after 24 h of treatment. For each sample, 20 mg proteins were separated on 12% SDSpolyacrylamide gels and transferred to a nitrocellulose filter.
Western blotting experiments were performed with the antibodies used for IHC reported hitherto, using a 1:1000 dilution for the anti-AIP antibody and a 1:500 dilution for the anti-AHR antibody respectively and HRP-linked secondary antibodies for protein detection. GAPDH was used as a housekeeping control. 
Results
Study population
In order to look for potential bias in the selection of patients treated by with SSA before surgery, the characteristics of treated and untreated patients and tumours were retrospectively compared (Table 1) . Female patients predominated in both groups. Although treated patients tended to be older than untreated patients, the difference was not significant (PZ0.055). SSA-treated and -untreated groups had similar proportions of subjects with proven normal AIP sequencing (including young patients). Plasma GH, PRL and IGF1 (%ULN) levels at diagnosis were similar in both groups. No significant difference existed between the two groups in terms of tumour volume, invasiveness or functional phenotypes. Gsp C tumours were also similarly distributed among treated and untreated patients. The significantly lower Ki67 index observed in treated vs untreated tumours (PZ0.002) was ascribed to the anti-proliferative effect of SSA on somatotropinomas.
General immunohistochemical findings
Examples of AIP and AHR immunostaining in four representative cases and in a NP control are shown in Fig. 1 . Some degree of AIP immunostaining was observed in all but two cases (96.8%). Diffuse cytoplasmic immunostaining was the most frequent pattern and low AIP expression was observed in 17 out of 62 cases (27.4%). Preoperative SSA was found to significantly influence AIP expression. Low AIP-IHC was twice as frequent in Owing to the retrospective character of the study, some data were missing. For continuous variables with missing values, the number of available cases is indicated within parentheses for each item.
untreated vs SSA-treated GH-PA (44.0 vs 20.5%, PZ0.016).
A similar trend was seen taking only those with proven normal AIP status, although the difference did not reach significance (44.4 vs 22.7%, PZ0.140). Hence, low AIPexpressing GH-PA were characterised in the whole series and in untreated cases taken as a subgroup (Table 2) . Low AIP-IHC was associated with disease aggressiveness. All low AIP-IHC tumours but one were macroadenomas. Suprasellar extension was more frequent in low AIP-IHC vs high AIP-IHC tumours (PZ0.0003), and this was confirmed in untreated cases (PZ0.019). Low AIP-IHC tumours also tended to be more invasive than those retaining AIP expression, although the difference reached significance in untreated tumours only (PZ0.028). A higher Ki67 index was found in invasive vs non-invasive GH-PA in the untreated group only (2.5% (1.0-8.0) vs 1.0% (0.0-3.0), PZ0.043). Accordingly, a significant negative correlation was found between the AIP score and the Ki67 index in the whole series (PZ0.011) and in untreated tumours (PZ0.036), but not in SSA-treated tumours (Table 3) . Significantly higher preoperative plasma GH, IGF1 (%ULN) and Ki67 index values were observed in low AIP-IHC vs high AIP-IHC tumours (PZ0.006, PZ0.022 and PZ0.019 vs high AIP-IHC respectively), with similar nonsignificant trends in the untreated group (Table 2) . Introducing preoperative SSA treatment as a covariant for each parameter, a significant negative association was confirmed between low AIP-IHC and higher Ki67 values (PZ0.047), with a similar trend for higher preoperative plasma GH (PZ0.065), but not for IGF1.
Some AHRc immunostaining was also observed in most tumours with available data (50 out of 53 cases; 94.3%), including 29 cases (54.7%) that had a high AHRc score. AHRn was detected in nearly half of the studied cases (26 out of 53, 49.1%), of which 18 (34.0%) had a high AHRn score. Correlations between AIP and AHR immunoscores are shown in Table 3 . Overall, a significant positive correlation was found between the AHRn and AHRc scores (PZ0.004) whereas AIP correlated significantly with AHRc (PZ0.012) and AHRt (PZ0.049), but not with AHRn. Correlations between AIP and AHR approached significance in untreated tumours (PZ0.05 for AHRt and PZ0.077 for AHRc). By contrast, AHRn strongly correlated with AHRc in treated tumours only (PZ0.0015).
Searching for factors able to influence AHR content, regardless of its intracellular localisation, we further analysed high AHR-IHC tumours, which accounted for 32.1% of the whole series (17/53). In high AHR-IHC tumours, microadenomas were more frequent (29.4 vs 8.3%, PZ0.045), suprasellar extension was less frequent (25.0 vs 60.0%, PZ0.02) and pure GH-secreting PA predominated over mixed secreting GH-PA (76.5 vs 44.4%, PZ0.029) when compared with low AHR-IHC. By contrast, no significant influence of gender, tumour invasiveness or preoperative hormone profile was observed. The AHRt score and the characteristics of high AHR-IHC tumours were not statistically influenced by preoperative SSA treatment (Table 4) . Table 5 . By definition, preoperative IGF1 (%ULN) significantly differed among the three groups (P!0.0001). Differences in disease control were related to the effect of treatment, as plasma GH and IGF1 (%ULN) were similar at diagnosis. Accordingly, DIGF1 (PZ0.0004) significantly differed among the three groups, with a similar but not significant trend for DGH (PZ0.082). Uncontrolled cases had significantly lower DIGF1 (PZ0.0007) and DGH (PZ0.031) than controlled and partially controlled tumours taken together. Tumour shrinkage was reported in a subset of tumours (7/26, 26.7%).
The proportion of low AIP-IHC tumours and the AIP score significantly differed among the three groups (PZ0.006 and PZ0.014 respectively). In particular, uncontrolled tumours had a significantly lower AIP expression than controlled and partially controlled tumours taken together (low AIP-IHC in 50 vs 4.3% and median AIP score 2.5 vs 4.0, PZ0.0003 and PZ0.008 respectively). High AIP-IHC was observed in all tumours showing preoperative shrinkage, contrasting with low AIP-IHC in 6 out of 19 tumours in the absence of shrinkage (31.6%). Accordingly, the AIP score was significantly higher in the presence (4.5 (3-5)) than in the absence (3.0 (1-5)) of tumour shrinkage (PZ0.014). In contrast, no significant difference in AHR expression was found that was attributable to the effect of preoperative SSA treatment in terms of IGF1 normalisation or tumour shrinkage.
The relationship between AIP-IHC and the response to SSA was also studied in tumours with proven normal AIP sequences. Half had received preoperative SSA (20/40 cases), of which seven showed a partial and seven a complete hormone response (i.e. 14 out of 20 responders), and tumour shrinkage was reported in 2 out of 15 cases. As shown in Fig. 2 , the AIP score was significantly higher in the presence of a partial or complete hormone response (PZ0.008 vs uncontrolled tumours) and in the presence of preoperative hormone shrinkage (PZ0.046). AHR immunostaining was unrelated to the outcome of treatment, although a trend towards a higher AHRc score in controlled and partially controlled tumours was observed when compared with uncontrolled tumours (PZ0.07) (data not shown).
In vitro effect of octreotide on GH-PA
In order to search for a direct effect of octreotide on AIP and AHR expression in GH-PA, primary cultures from six GH-PA -one Gsp C and five Gsp K -were treated with 10 nM octreotide in vitro. Data are illustrated in Fig. 3 . Two GH-PA (both Gsp K ) were suitable for time-dependent experiments, showing a significant increase in AIP expression after 24 h of treatment. The remaining tumours were studied at baseline and after 24 h of treatment. Measurable levels of AIP were detected in all tumours, whereas in two cases, no reliable quantification of AHR could be obtained. A variable but significant increase in AIP expression was observed in all cases (median 2.03-fold; range 1.2-13.9, PZ0.027), whereas AHR expression was increased in a single Gsp K tumour only (median 1.2-fold, range 1.0-2.8, P, NS). The Gsp C tumour showed a 2.9-fold increase in AIP expression and no increase in AHR.
Influence of Gsp mutations on AIP and AHR expression
The characteristics of Gsp C and Gsp K somatotropinomas are summarised in Table 6 . No significant difference was observed at diagnosis between the two groups. Among tumours treated with SSA preoperatively (9 Gsp C and 14 Gsp K ), Gsp C tumours tended to be associated with a higher reduction in plasma GH values and a higher rate of shrinkage before surgery (PZ0.09 vs Gsp K for both parameters). Significantly, lower Ki67 values were also observed in Gsp C when compared with Gsp K tumours in SSA-treated cases (PZ0.006).
No significant effect of Gsp status was observed on AIP expression. In particular, as observed in unselected GH-PA, a lower AIP score was observed in Gsp C tumours in the presence of a suprasellar extension (PZ0.034 vs intrasellar Gsp C tumours, data nor shown). The only effect of Gsp status was a significantly lower AHRn score in Gsp C tumours (PZ0.025 vs Gsp K tumours), suggesting cytoplasmic retention of AHR in Gsp C GH-PA. This finding was confirmed in the presence of preoperative SSA treatment (PZ0.031 vs treated Gsp K tumours). In contrast, preoperative SSA treatment was associated with a significant increase in AHR expression in Gsp K tumours (PZ0.013 for AHRc and PZ0.037 for AHRt vs untreated Gsp K tumours respectively), with no significant change in its nuclear localisation.
Discussion
This extensive series of tumours from patients with sporadic acromegaly provides substantial new information on the effects of SSA on the expression of AIP and its best characterised molecular partner, AHR. In addition, it evaluates for the first time the influence of somatic Gsp mutations on such parameters.
Data obtained across the whole series are consistent with previous reports showing AIP down-regulation in aggressive somatotropinomas (Jaffrain-Rea et al. 2009 , Kasuki Jomori de Pinho et al. 2011 . However, tumour volume and proliferative activity were found to have a stronger impact on AIP expression than invasive features.
AIP loss was significantly associated with suprasellar extension and higher Ki67 values regardless of preoperative SSA treatment, but it was significantly associated with invasiveness in untreated cases only. This indicates that preoperative pharmacological treatment introduces an important limitation in the use of AIP immunostaining as a marker of invasiveness in somatotropinomas. This is similar to the effect of SSA pretreatment on the Ki67 index, which can be significantly reduced by the antiproliferative effects of SSA in GH-PA (Losa et al. 2001 , Jaffrain-Rea et al. 2002 . Overall, low AIP expression was also associated with higher preoperative GH/IGF1 levels. Although this could, in part, be due to the lower proportion of low AIP-IHC tumours treated by SSA preoperatively, a trend towards higher preoperative GH levels in low AIP-IHC tumours was seen after correction for preoperative treatment on the whole series and in untreated tumours. Taken together, these findings indicate that low AIP-IHC tumours share common characteristics with AIP mut GH-PA .
Notably, the higher percentage of GH/PRL adenomas reported in AIP mut PA has not been observed among low AIP-IHC somatotropinomas (Kasuki et al. 2012 , this study). The mechanisms of AIP down-regulation in non-AIP mut somatotropinomas have been poorly investigated, but overexpression of the miR-107 has been recently proposed . Dysregulation of AHR expression has been reported in a number of tumours (Harper et al. 2006 , Dietrich & Kaina 2010 and reduced AHR (Jaffrain-Rea et al. 2009) and ARNT (Heliövaara et al. 2009 , Raitila et al. 2010 ) expression have been observed in AIP mut PA. In this study, only 32% of sporadic GH-PA displayed a high AHR content. We found these tumours to be smaller and to include a higher proportion of pure GH-secreting PA than those displaying a low AHR content, suggesting that AHR down-regulation may also occur during the evolution of sporadic GH-PA. A significant correlation was found between AIP and AHRc, further supporting a role for AIP in the stabilisation of AHR in PA (Jaffrain-Rea et al. 2009 ). This may be attenuated by preoperative SSA treatment, potentially suggesting that the stability of the AIP/AHR complex may be influenced by SSA or that SSA differentially affect AIP and AHR expression in GH-PA. By contrast, despite AHR signalling being potentially enhanced by AIP (Petrulis & Perdrew 2002) , AHRn was unrelated to AIP, irrespective of SSA treatment. Thus, the potential influence of AIP on AHR signalling in sporadic GH-PA remains unclear.
Data from a large series of sporadic GH-PA with proven normal AIP sequences in the majority of cases support recent evidence that AIP expression is increased by preoperative SSA treatment . Notably, similar results were obtained whether lanreotide or octreotide (Jaffrain-Rea et al. 2010, this study) was used for the preoperative treatment of acromegalic patients. In contrast, no change in AIP expression was observed in two AIP mut cases operated before and after treatment . Supporting recent findings in GH 3 cells , this study provides the first evidence for a variable but significant up-regulation of AIP expression by octreotide in human GH-PA in vitro, with a median twofold increase. A significant relationship was also found between AIP immunostaining and the outcome of pre-surgical SSA treatment, both in terms of hormonal control and tumour shrinkage, further indicating AIP to be an important mediator of SSA in GH-PA. Indeed, the AIP score was significantly lower in uncontrolled tumours when compared with partially and fully controlled tumours and significantly higher in the presence of preoperative shrinkage. In particular, none of the tumours showing preoperative shrinkage had low AIP immunostaining, contrasting with 30% of those showing no effect of SSA on tumour volume. These results echo those obtained in a large series of AIP mut acromegalic patients, in which the median shrinkage with SSA was highly statistically significantly lower than in control acromegalic patients (0 vs 41%, P!0.000001; Daly et al. 2010) . In this study, no difference was found according to the degree of disease control obtained at the time of surgery (IGF1 normalisation or reduction by R30% compared with baseline values). Owing to the retrospective and multicentre characteristics of our study, we might have been unable to distinguish between these two groups. Preoperative SSA treatment was not standardised, so that differences in the degree of response obtained before surgery did not necessarily reflect differences in SSA sensitivity. Additional factors may also be involved in the modulation of AIP by SSA. Chahal et al. (2012) found a positive correlation between AIP expression and IGF1 changes in female acromegalics only. A similar nonsignificant trend was present in our series (data not shown), but the higher proportion of female cases could have introduced some bias and no gender specificity could be shown. However, the unusual male predominance in AIP mut somatotropinomas and reported interactions between AIP, AHR and steroid receptors (Beischlag et al. 2008) , in particular oestrogen receptor a (Matthews & Gustafsson 2006 , Cai et al. 2011 , suggest potential variations in AIP expression or function according to patient's gender and the steroid milieu, which deserve further investigation. Because the cyclin kinase inhibitor p27 Kip1 can be induced by SSA (Ferrante et al. 2006) and by AHR signalling (Marlowe & Puga 2005) , we proposed the hypothesis that AHR itself could be a target of SSA in GH-PA. However, no significant difference in AHR content or in its nuclear localisation was observed between SSAtreated vs -untreated tumours, or according to the effect of treatment. Although there was some evidence that AHRc immunostaining could be higher in SSA-treated tumours, this was also unrelated to the effect of treatment and might be due to the higher AIP expression observed in treated GH-PA. Unexpectedly, a strong correlation was found between AHRn and AHRc in treated tumours. This may reflect the complex regulation of nucleocytoplasmic shuttling of AHR, which involves several exogenous and endogenous activators (Beischlag et al. 2008 , Nguyen & Bradfield 2008 . Overall, these data argue against a significant role for AHR in the pharmacological response to SSA in GH-PA. Most of the pharmacological effects of octreotide and lanreotide on GH-PA are mediated by somatostatin receptor (SSTR) subtypes 2 and 5 (Ben-Shlomo & Melmed 2010). AIP immunostaining was identified as a predictive factor of post-operative SSA sensitivity independent of SSTR2 (Kasuki et al. 2012 ) and a slightly higher SSTR5 expression was observed in AIP mut tumours , suggesting that AIP-related differences in SSA sensitivity are not due to important changes in SSTRs.
Potential variations in the expression of receptors reported to negatively affect the pharmacological response to SSA, such as truncated variants of SSTR5 (Durán-Prado et al. 2010 or the dopamine receptor D2R (Zatelli et al. 2005) , have not been reported yet. An alternative molecular link between AIP expression and SSA signalling is ZAC1, a tumour suppressor gene involved in the antiproliferative action of octreotide (Theodoropoulou et al. 2006) , whose expression correlates with tumour shrinkage and IGF1 changes in treated GH-PA (Theodoropoulou et al. 2009 ). ZAC1 has been recently proposed to act downstream of AIP in GH 3 cells . However, potential correlations between AIP and ZAC1 expression in human GH-PA remain to be further explored. A relationship between AIP, AHR and cAMP signalling, the best characterised pathway in GH-PA and an important target of SSA, is suggested by experimental evidence indicating that i) cAMP is a non-ligand activator of AHR able to induce transcriptional responses different from exogenous ligands (Oesch-Bartlomowicz et al. 2005) , ii) nucleocytoplasmic shuttling of AHR induced by cAMP is inhibited by PDE2, which is stabilised by AIP (de Oliveira et al. 2007 ) and iii) AIP interactions with PDE4A5 can be disrupted by AIP mutations (Leontiou et al. 2008) . There is also very recent evidence that AIP reduces forskolininduced cAMP signalling in GH 3 cells, although forskolin did not influence AIP expression (Formosa et al. 2013) . However, intracellular cAMP concentrations have not been reported in the presence of AIP abnormalities in GH-PA and the potential effect of cAMP signalling on AIP expression in these tumours is unknown. Because Gsp mutations induce a constitutive activation of the cAMP/PKA pathway, we studied AIP and AHR expression according to Gsp status. In agreement with most reports, no specific phenotype was observed in Gsp C tumours, although they tended to respond better than Gsp K tumours to preoperative SSA treatment (Barlier et al. 1998 , Lania et al. 2003 . Accordingly, treated Gsp C tumours had significantly lower Ki67 than their Gsp K counterpart. AIP expression was similar in Gsp C and Gsp K tumours. Because only large Gsp C tumours had a low AIP expression, down-regulation of AIP appears as a late event in Gsp Crelated tumorigenesis. Notably, no Gsp mutations were found in a small series of AIP mut GH-PA, further suggesting that these are independent pathogenetic events . Preoperative SSA treatment had no differential effect on AIP expression in Gsp C and Gsp K tumours, and the effect of octreotide on AIP expression was unremarkable in the Gsp C tumour studied in vitro. In contrast, some effect of Gsp status could be found on AHR expression and localisation. In Gsp K tumours, preoperative SSA was associated with a significantly higher AHR content and AHR was increased by octreotide in one of three Gsp K tumours studied in vitro. Therefore, SSA may induce AHR in a subset of Gsp K GH-PA. Unexpectedly, AHRn expression was lower in Gsp C vs Gsp K GH-PA, regardless of AHR content, suggesting cytoplasmic retention of AHR in Gsp C tumours. A potential explanation is that Gsp C tumours activate regulatory mechanisms that operate to counteract the increase in cAMP concentration (Lania et al. 2003 , Pertuit et al. 2009 ), among which is an increased PDE activity, which might in turn inhibit AHRn shuttling. In addition, cAMP signalling involves different subcellular compartments, which may differentially regulate endocrine functions and AHR activation in somatototroph cells. Indeed, cytoplasmic retention of AHR was also observed in treated Gsp C tumours. The biological implications of these findings remain to be further investigated.
In conclusion, this study further supports a role for AIP down-regulation in the pathogenesis of sporadic acromegaly, with low AIP-expressing tumours sharing phenotypic features with AIP mut somatotropinomas. Overall, AIP down-regulation is associated with a reduced AHRc expression, with no significant effect on its nuclear localisation. AHR, but not AIP, appears to be differentially regulated according to Gsp status. In contrast, AIP, but not AHR, is an important mediator of SSA in GH-PA.
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